FBRX, US34962G2084

argenx completes USD 77.00 acquisition. Forte Biosciences stock leaves Nasdaq

Published on 10/01/2026 at 21:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx paid USD 77.00 per share on August 27, 2026. Forte Biosciences stock left Nasdaq after 87.13 percent of shares were tendered in cash.

FBRX, US34962G2084, Illustration mit AI erstellt.

Forte Biosciences (ISIN US34962G2084) became a wholly owned subsidiary of argenx after argenx completed its USD 77.00-per-share cash acquisition on August 27, 2026, according to StockTitan. The transaction also set the path for Forte Biosciences stock to leave the Nasdaq Capital Market.

Cash deal closes at USD 77.00

The tender offer attracted 19,894,879 validly tendered shares by August 26, 2026. Together with shares already owned by argenx and its affiliates, that represented 87.13 percent of Forte's issued and outstanding common stock, according to StockTitan.

The merger followed the cash tender offer under Section 251(h) of the Delaware General Corporation Law. Each remaining eligible share was converted into the right to receive the same USD 77.00 cash consideration, while specified excluded and appraisal shares followed separate treatment described in the filing.

Nasdaq exit changes the stock story

The acquirer used approximately USD 2.2 billion of cash on hand for the offer, equity awards, pre-funded warrants and related payments. Forte requested that Nasdaq suspend trading and file Form 25 to delist the shares, while a Form 15 filing dated September 8, 2026 reported zero holders of record for the relevant registration notice.

That sequence matters because the transaction, rather than quarterly operating performance, now defines the public-market outcome for FBRX. The USD 77.00 consideration gives the completed deal a clear cash value, while the 87.13 percent tender level shows that the offer crossed the ownership threshold needed for the merger structure.

FB102 remains the operating asset

Forte's business is centered on FB102, an anti-CD122 antibody designed to address autoimmune and inflammatory diseases through the IL-2 and IL-15 pathways, according to the company's investor presentation. The program included clinical work in celiac disease, vitiligo and alopecia areata, with topline data milestones described for 2026.

The investor presentation also described a Phase 2 celiac disease study, a Phase 1b vitiligo study and a Phase 1b alopecia areata study. These milestones now sit inside argenx's broader immunology portfolio rather than an independently traded Forte equity story.

Forte Biosciences stock leaves Nasdaq

Forte Biosciences stock is therefore treated as a completed acquisition situation dated August 27, 2026, rather than as an actively traded Nasdaq security. The company remains identifiable by ticker FBRX and ISIN US34962G2084 in filing and market records, but the acquisition determines the investor outcome.